Stockscreener 앱 받기
9.02
4.25%
-0.40
시간 외 거래:
9.02
전일 마감가:
$9.42
열려 있는:
$9.45
하루 거래량:
96,923
Relative Volume:
0.81
시가총액:
$130.48M
수익:
$166.88M
순이익/손실:
$-74.18M
주가수익비율:
-1.7791
EPS:
-5.07
순현금흐름:
$1.14M
1주 성능:
-0.55%
1개월 성능:
+7.38%
6개월 성능:
-33.68%
1년 성능:
-64.28%
1일 변동 폭
$9.00
$9.465
1주일 범위
$9.00
$9.58
52주 변동 폭
$7.8701
$25.65
Anika Therapeutics Inc Stock (ANIK) Company Profile
명칭
Anika Therapeutics Inc
전화
(781) 457-9000
주소
32 WIGGINS AVENUE, BEDFORD, MA
ANIK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
9.05 | 135.82M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
141.09 | 63.55B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 44.47B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.00 | 40.17B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 22.99B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
439.99 | 20.14B | 3.08B | 1.24B | 1.07B | 25.61 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-17 | 개시 | B. Riley Securities | Buy |
| 2024-11-01 | 재확인 | Barrington Research | Outperform |
| 2023-08-14 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2023-03-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-11-09 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-10-14 | 재개 | Stephens | Equal-Weight |
| 2022-03-09 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2022-03-09 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2021-11-16 | 개시 | Stephens | Overweight |
| 2021-07-16 | 개시 | UBS | Neutral |
| 2020-12-16 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-08 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-01-21 | 업그레이드 | Sidoti | Neutral → Buy |
| 2020-01-10 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-11-05 | 개시 | BWS Financial | Sell |
| 2019-09-24 | 재확인 | Barrington Research | Outperform |
| 2019-09-23 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2019-07-25 | 업그레이드 | First Analysis Sec | Neutral → Strong Buy |
| 2019-02-22 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-02-22 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2018-07-27 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-06-20 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-06-20 | 다운그레이드 | First Analysis Sec | Overweight → Equal-Weight |
| 2018-05-04 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2018-02-23 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2018-01-24 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-10-27 | 재확인 | Barrington Research | Outperform |
| 2016-05-09 | 업그레이드 | Singular Research | BUY - Long-Term → Buy |
| 2016-04-27 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2016-02-26 | 재확인 | Barrington Research | Outperform |
모두보기
Anika Therapeutics Inc 주식(ANIK)의 최신 뉴스
Anika Therapeutics Inc. stock trend outlook and recovery path2025 Short Interest & Community Consensus Picks - newser.com
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. - GlobeNewswire
United States Adhesion Barrier Market Set for Explosive Growth: - openPR.com
Can Anika Therapeutics Inc. (AKP) stock sustain double digit ROEJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Weiss Ratings Reiterates "Sell (E+)" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Orthopedic Digit Implants Market Report 2025-2033, with Profiles of Extremity Medical, Stryker, Zimmer, Smith & Nephew, Depuy, Arthrex, Acumed, Anika Therapeutics, VILEX, and Paragon 28 - Ortho Spine News
Orthopedic Digit Implants Market Report 2025-2033, with - GlobeNewswire
What technical models suggest about Anika Therapeutics Inc.’s comebackM&A Rumor & Stock Portfolio Risk Control - newser.com
Published on: 2025-10-05 06:33:40 - newser.com
Predicting Anika Therapeutics Inc. trend using moving averagesJuly 2025 Analyst Calls & AI Enhanced Trading Signals - newser.com
Anika Therapeutics Inc. stock trendline breakdownEarnings Recap Report & Fast Gaining Stock Reports - newser.com
Trend analysis for Anika Therapeutics Inc. this weekFed Meeting & Risk Managed Investment Entry Signals - newser.com
Leading vs lagging indicators on Anika Therapeutics Inc. performanceM&A Rumor & Real-Time Sentiment Analysis - newser.com
Analyzing Anika Therapeutics Inc. with multi timeframe chartsMarket Sentiment Report & Community Verified Trade Alerts - newser.com
Is Anika Therapeutics Inc. (AKP) stock attractive for growth fundsRisk Management & Real-Time Chart Breakout Alerts - newser.com
Using data filters to optimize entry into Anika Therapeutics Inc.New Guidance & High Conviction Investment Ideas - newser.com
Multi factor analysis applied to Anika Therapeutics Inc.M&A Rumor & Safe Investment Capital Preservation Plans - newser.com
Published on: 2025-10-03 01:07:01 - newser.com
How to monitor Anika Therapeutics Inc. with trend dashboardsEarnings Trend Report & High Conviction Investment Ideas - newser.com
What analysts say about Anika Therapeutics Inc stockMean Reversion Trades & Big Gains Small Investment - earlytimes.in
Can T I Global Limited Survive Disruption in Its Core IndustryRSI Overbought/Oversold & Double Digit Trading Ideas - earlytimes.in
What drives Anika Therapeutics Inc stock priceVolume Spike Alerts & Investment Recommendations You Can Trust - earlytimes.in
Published on: 2025-10-03 05:32:20 - earlytimes.in
Is Anika Therapeutics Inc AKP a good long term investmentPortfolio Diversification Tips & Capital Allocation Recommendations - earlytimes.in
Published on: 2025-09-27 05:01:43 - newser.com
What analysts say about Anika Therapeutics Inc AKP stockStop Loss Placement Tips & Exceptional Return Opportunities - Early Times
ANIKA (ANIK) ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Anika Therapeutics Inc. $ANIK Stock Position Reduced by Goldman Sachs Group Inc. - Defense World
Barrington Research Reiterates "Outperform" Rating for Anika Therapeutics (NASDAQ:ANIK) - MarketBeat
Anika Therapeutics (ANIK) Rating Maintained with $15 Target by B - GuruFocus
Will Anika Therapeutics Inc. stock go up soonJuly 2025 Snapshot & Stock Portfolio Risk Control - newser.com
Barrington Maintains Anika Therapeutics(ANIK.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Anika Therapeutics Inc (ANIK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Anika Therapeutics Inc 주식 (ANIK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Nunes Anne | SVP, Chief Operations Officer |
Mar 17 '25 |
Option Exercise |
0.00 |
3,637 |
0 |
21,722 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 17 '25 |
Option Exercise |
0.00 |
6,448 |
0 |
49,847 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 17 '25 |
Option Exercise |
0.00 |
25,132 |
0 |
209,472 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 11 '25 |
Option Exercise |
0.00 |
2,561 |
0 |
18,837 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 11 '25 |
Option Exercise |
0.00 |
7,663 |
0 |
45,649 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 11 '25 |
Option Exercise |
0.00 |
30,060 |
0 |
197,015 |
| Nunes Anne | SVP, Chief Operations Officer |
Mar 10 '25 |
Option Exercise |
0.00 |
3,296 |
0 |
17,235 |
| Colleran David | EVP, General Counsel, Corp Sec |
Mar 10 '25 |
Option Exercise |
0.00 |
5,465 |
0 |
39,590 |
| Blanchard Cheryl R | President, CEO, Director |
Mar 10 '25 |
Option Exercise |
0.00 |
20,002 |
0 |
172,826 |
1.54%
1.16%
자본화:
|
볼륨(24시간):